The pharmacological properties of the novel selective 5-HT3 receptor agonist, alosetron, and its effects on normal and perturbed small intestinal transit in the fasted rat

Neurogastroenterology and Motility

Volumn 11, Issue 3, 1999, Pages 207-217

  Clayton, Nick M ^a   Sargent, R ^a   Butler, A ^a   Gale, J ^b   Maxwell, M P ^a   Hunt, A A E ^a   Barrett, V J ^a   Cambridge, D ^a   Bountra, C ^a   Humphrey, P P A ^a  

^a GLAXOSMITHKLINE   (United Kingdom)

^b PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

Author keywords

5HT3 antagonists; Alosetron; Bezold Jarisch reflex; Egg albumin sensitization; Irritable bowel syndrome; Small intestinal propulsion

Indexed keywords

2 METHYLSEROTONIN; ALOSETRON; ION CHANNEL; ONDANSETRON; OVALBUMIN; RADIOLIGAND; SEROTONIN 3 ANTAGONIST; SEROTONIN 3 RECEPTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRADYCARDIA; CONCENTRATION RESPONSE; CONTROLLED STUDY; DEPOLARIZATION; DOSE TIME EFFECT RELATION; INTESTINE FUNCTION; INTESTINE MOTILITY; INTESTINE TRANSIT TIME; INTRADUODENAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; LIGAND BINDING; MALE; NONHUMAN; PRIORITY JOURNAL; PROVOCATION TEST; RAT; RECEPTOR AFFINITY; SMALL INTESTINE; VAGUS NERVE;

ADRENERGIC ALPHA-AGONISTS; ANIMALS; CARBOLINES; CLONIDINE; DRUG EVALUATION, PRECLINICAL; FASTING; GASTROINTESTINAL TRANSIT; INTESTINE, SMALL; ONDANSETRON; OVALBUMIN; RADIOLIGAND ASSAY; RATS; REFERENCE VALUES; REFLEX; SEROTONIN ANTAGONISTS; VAGUS NERVE;

EID: 0033001772     PISSN: 13501925     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2982.1999.00148.x     Document Type: Article

References (42)

1. 1 Drossmann DA, Thompson WG, Talley NJ, Fuunch-Jensen P, Janssens J, Whitehead WE. Identification of subgroups of functional bowel disorders. Gastroenterol Intl 1990; 3: 159-72.
2. 2 Talley NJ, Phillips SF, Melon LJ, et al. Diagnostic value of the Manning criteria in irritable bowel syndrome. Gut 1990; 31: 77-81.
3. 3 Thompson WG, Dotevall G, Drossman DA, Heaton KW, Kruis W. Irritable bowel syndrome: guidelines for the diagnosis. Gastroenterol Intl 1989; 2: 92-5.
4. 4 Mayer EA, Gebhart GF. Basic and clinical aspects of visceral hyperalgesia. Gastroenterology 1994; 107: 271-93.
5. 5 Camilleri M, Choi M-G. Review article: irritable bowel syndrome. Aliment Pharm Ther 1997; 11: 3-15.
6. 6 Ritchie J, Pain from distention of the pelvic colon by inflating a balloon in the irritable colon syndrome. Gut 1973; 14: 125-32.
7. 7 Whitehead WE, Holtkotter B, Enck P, et al. Tolerance for rectosigmoid distension in irritable bowel syndrome. Gastroenterology 1990; 98: 1187-92.
8. 8 Bueno L, Fioramonti J, Delvaux M, Frexinos J. Mediators and pharmacology of visceral sensitivity: from basic to clinical investigations. Gastroenterology 1997; 112: 1714-43.
9. 9 Taub E, Cuevas JL, Cook EW, Crowell M, Whitehead WE. Irritable bowel syndrome defined by factor analysis. Gender and race comparisons. Dig Dis Sci 1995; 40: 2647-55.
10. 10 Mertz H, Naliboff B, Munakata J, Niazi N, Mayer EA. Altered rectal perception is a biological marker of patients with irritable bowel syndrome. Gastroenterology 1995; 109: 40-52.
11. 11 Moss HE, Sanger GJ. The effects of granisetron, ICS 205-930 and ondansetron on the visceral pain reflex induced by duodenal distension. Br J Pharm 1990; 100: 497-501.
12. 12 Scott CM, Grundy D, Boissonade F, Bountra C. Alosetron inhibits the colorectal distension-evoked depressor response and spinal c-fos expression in the anesthetized rat. Gastroenterology 1997; 112: A822.
13. 13 Kilpatrick GJ, Hagan RM, Oxford AW, North PJC, Tycers MBGR. 68755 Hydrochloride. Drugs Future 1992; 17: 660-4.
14. 14 Bardhan K, Bodemar G, Geldof H, Schutz E, Snell C, Darekar B. A double-blind, placebo-controlled study to evaluate the efficacy of alosetron in the treatment of irritable bowel syndrome (IBS). Gastroenterology 1996; 110: A630.
15. 15 Gunning SJ, Humphrey PPA. Evidence for 5-HT3 receptor mediated release of an inhibitory transmitter in guinea-pig isolated ileum. Br J Pharm 1987; 91: 359P.
16. 16 Drakontides AB, Gerson MD. 5-hydroxytryptamine receptors in the mouse duodenum. Br J Pharm 1968; 33: 480-92.
17. 17 Kadowaki M. Participation of 5-HT3, 5-HT4, and nicotinic receptors in the peristaltic reflex of guinea pig distal colon. Am J Physiol 1996; 271: G849-G857.
18. 18 Foster JM, Houghton LA, Whorwell PJ. Alosetron slows colonic transit in patients with irritable bowel syndrome (IBS). Gastroenterology 1997; 112: A732.
19. 19 Marie M, Gall DG, Scott RB. The effect of food protein-induced intestinal anaphylaxis on rate of transit. Can J Physiol Pharmacol 1989; 67: 1437-41.
20. 3 receptor antagonist, in the rat. Digestive Dis Sci 1996; 41:1903 (A95).
21. 21 Ireland SJ, Tyers MB. Pharmacological characterisation of 5-Hydroxytryptamine induced depolaraistion of the rat isolated vagus nerve. Br J Pharmacol 1987; 90: 229-39 ref.
22. 22 Butler A, Hill JM, Ireland SJ, Jordan CC, Tyers MB. Pharmacological characterisation of GR38032F, a novel antagonist at 5-HT receptors. Br J Pharmacol 1988; 94: 397-412.
23. 4 receptors are not involved in the control of small intestinal transit in the fasted conscious rat. Neurogastroenterol Mot 1996; 8: 1-8.
24. 24 Miller MS, Galligan JJ, Burks TF. Accurate measurement of intestinal transit in the rat. J Pharmacol Meth 1981; 6: 211-7.
25. 25 Kennedy I, Roberts F. Comparison of dose-response curves for full and partial agonists. Br J Pharmacol 1985; 86: 755P.
26. 26 Talley NJ. Review article: 5-hydroxytryptamine agonists and antagonists in the modulation of gastrointestinal motility and sensation: clinical implications. Aliment Pharmacol Ther 1992; 6: 273-89.
27. 27 Brown NJ, Horton A, Rumsey RD, Read NW. Granisetron and ondansetron: effects on the ileal brake mechanism in the rat. J Pharm Pharmacol 1993; 45: 521-4.
28. 3 antagonist (GR38032F) on small intestinal transit and release of gastrointestinal peptides. Dig Dis Sci 1989; 34: 1511-5.
29. 3H] para-amino clonidine: a novel ligand which binds with high affinity to α adrenergic receptors. Life Sci 1979; 25: 769-74.
30. 30 Leclerc G, Rouot B, Schwartz J, Velly J, Wermuth CG. Studies on some para-substituted clonidine derivatives that exhibit an α-adrenoceptor stimulant activity. Br Pharmacol 1980; 71: 5-9.
31. 31 Scott RB, Diamant SC, Gall DG. Motility effects of intestinal anaphylaxis in the rat. Am J Physiol 1988; 255: G505-G511.
32. 32 Scott RB, Gall DG, Marc M. Mediation of food protein induced jejunal smooth muscle contraction in sensitised rats. Am J Physiol 1990; 259: G6-G14.
33. 33 Fargeas MJ, Theodourou V, Fioramonto JU, Bueno L. Relationship between mast cell degranulation and jejunal myoelectric alterations in intestinal anaphylaxis in rats. Gastroenterology 1992; 102: 157-62.
34. 3 receptor in normal and disordered gastrointestinal function. In: King FD, Jones BJ, Sanger GJ, eds. 5-Hydroxytrptamine-3 Receptor Antagonists. CRC Press, 1994: 319-58.
35. 35 Castex N, Fioramonti J, Fargeas MJ, Bueno L. c-fos expression in specific rat brain nuclei after intestinal anaphylaxis: involvement of 5-HT3 receptors and vagal afferent fibres. Brain Res 1995; 688: 149-60.
36. 36 Anthony M, Hinterberger H, Lance JW. Plasma serotonin in migraine and stress. Arch Neurol 1967; 16: 544-52.
37. 37 Kuwabara T, Otaka M, Itoh H. Regulation of 60-KD heat shock protein expression by systemic stress and 5-hydroxyptamine in rat colonic mucosa. Gastroenterology 1994; 29: 721-6.
38. 38 Reisner G, Hamprecht B. Substance P and serotonin synergistically activate a cation permeability in a neuronal cell line. Naunyn-Schmiedeberg's Arch Pharmacol 1988; 337 (Suppl.): R109.
39. 39 Wood JD. Messenger function of serotonin in the enteric nervous system. In: Paoletti DR, Vanhoutte PM, Brunella N, Maggi FM, eds. Serotonin: from Cell Biology to Pharmacology and Therapeutics Dordrecht: Kluwer Publications, 1990: 241-9.
40. 3) Receptor antagonist ondansetron (GR38032F) in diarrhoea-predominant irritable bowel syndrome (IBS). Gastroenterology 1990; 98: A394.
41. 3 antagonists: a role in irritable bowel syndrome and non-ulcer dyspepsia. (Question). Gut 1991; 32: A1228.
42. 3 antagonist in irritable bowel syndrome (IBS). Gastroenterology 1991; 100: A468.